Table 2. Safety of inclisiran.

N/A = not available

Author, Year	Trial name	Most common adverse events (number of events)
		Adverse events	Inclisiran Group	Placebo Group
Fitzgerald et al., 2014 [6]	N/A	Infusion site hematoma	1	1
							Paresthesia	3
							Rash	12	4
							Headache	5	2
Fitzgerald et al., 2016 [7]	N/A	Nasopharyngitis	7	N/A
		Diarrhea	4
		Back pain	5
		Headache	6
Fitzgerald et al., 2017 [7,8]	ORION-1	Injection site reaction	19	--
		Myalgias	27	6
Raal et al., 2019 [9]	ORION-2	Paresthesia	1 1	N/A
		Unstable angina	1
Wright et al., 2020 [10]	ORION-7	Cough	4	N/A
							Nasopharyngitis	1
							Headache	2
							Fatigue	2
Raal et al., 2020 [11]	ORION-9	Nasopharyngitis	28	20
		Influenza	13	21
		Upper respiratory tract infections	16	16
		Back pain	17	10
		Injection site reaction	22	0
Ray et al., 2020 [12]	ORION-10	Death from cardiovascular events	7	5
		Diabetes mellitus	120	108
		Bronchitis	46	30
		Injection site reaction (mild and moderate)	20	7
Ray et al., 2020 [12]	ORION-11	Death from cardiovascular events	9	10
		Injection site reaction	38	4
		Nasopharyngitis	91	90
		Diabetes mellitus	88	94